Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Deferred Tax Liability: 2023-2024

  • Gyre Therapeutics' Non-Current Deferred Tax Liability rose 232.00% to $8.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.3 million, marking a year-over-year increase of 232.00%. This contributed to the annual value of $8.3 million for FY2024, which is 232.00% up from last year.
  • Per Gyre Therapeutics' latest filing, its Non-Current Deferred Tax Liability stood at $8.3 million for Q4 2024, which was up 232.00% from $2.5 million recorded in Q4 2023.
  • Over the past 5 years, Gyre Therapeutics' Non-Current Deferred Tax Liability peaked at $8.3 million during Q4 2024, and registered a low of $2.5 million during Q4 2023.
  • For the 2-year period, Gyre Therapeutics' Non-Current Deferred Tax Liability averaged around $5.4 million, with its median value being $5.4 million (2023).
  • Data for Gyre Therapeutics' Non-Current Deferred Tax Liability shows a peak YoY spiked of 232.00% (in 2024) over the last 5 years.
  • Quarterly analysis of 2 years shows Gyre Therapeutics' Non-Current Deferred Tax Liability stood at $2.5 million in 2023, then surged by 232.00% to $8.3 million in 2024.